New technology that rapidly and simply detects disease-specific molecular alterations in two forms of leukemia could give ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of ...

Using a form of CRISPR technology, the ultimate vision of the four-year ... This technology holds the promise of personalized treatments for patients with rare metabolic diseases such as type I ...

New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

As of October 2024, there are more than thirty FDA-approved gene therapies, spanning a diverse array of diseases such as ...

In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.

For the biopharma industry to match the pace of genomic innovations and speed new therapies to market, it will need to ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.